

Rolando Herrero Acosta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/214320/publications.pdf>

Version: 2024-02-01

311
papers

35,494
citations

2675

95
h-index

3732

179
g-index

315
all docs

315
docs citations

315
times ranked

22785
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. <i>New England Journal of Medicine</i> , 2003, 348, 518-527.	27.0	5,264
2	Human Papillomavirus and Oral Cancer: The International Agency for Research on Cancer Multicenter Study. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1772-1783.	6.3	1,013
3	Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 541-550.	2.5	908
4	Alcohol Drinking in Never Users of Tobacco, Cigarette Smoking in Never Drinkers, and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. <i>Journal of the National Cancer Institute</i> , 2007, 99, 777-789.	6.3	837
5	Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer in Female Partners. <i>New England Journal of Medicine</i> , 2002, 346, 1105-1112.	27.0	707
6	Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 743.	7.4	581
7	Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. <i>The Lancet Global Health</i> , 2016, 4, e453-e463.	6.3	580
8	Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention. <i>Journal of the National Cancer Institute</i> , 2006, 98, 303-315.	6.3	568
9	Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. <i>Lancet, The</i> , 2002, 359, 1085-1092.	13.7	561
10	Population-Based Study of Human Papillomavirus Infection and Cervical Neoplasia in Rural Costa Rica. <i>Journal of the National Cancer Institute</i> , 2000, 92, 464-474.	6.3	515
11	The carcinogenicity of human papillomavirus types reflects viral evolution. <i>Virology</i> , 2005, 337, 76-84.	2.4	487
12	Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. <i>Lancet, The</i> , 2002, 359, 1093-1101.	13.7	482
13	HPV DNA Testing in Cervical Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 87.	7.4	466
14	Rapid Clearance of Human Papillomavirus and Implications for Clinical Focus on Persistent Infections. <i>Journal of the National Cancer Institute</i> , 2008, 100, 513-517.	6.3	436
15	Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. <i>PLoS ONE</i> , 2013, 8, e68329.	2.5	387
16	A Prospective Study of Age Trends in Cervical Human Papillomavirus Acquisition and Persistence in Guanacaste, Costa Rica. <i>Journal of Infectious Diseases</i> , 2005, 191, 1808-1816.	4.0	354
17	Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. <i>International Journal of Cancer</i> , 2006, 119, 2677-2684.	5.1	332
18	Epidemiologic Profile of Type-specific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa Rica. <i>Journal of Infectious Diseases</i> , 2005, 191, 1796-1807.	4.0	322

#	ARTICLE	IF	CITATIONS
19	Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. <i>International Journal of Epidemiology</i> , 2010, 39, 166-181.	1.9	322
20	Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection. <i>Journal of the National Cancer Institute</i> , 2010, 102, 315-324.	6.3	320
21	Herpes Simplex Virus-2 as a Human Papillomavirus Cofactor in the Etiology of Invasive Cervical Cancer. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1604-1613.	6.3	299
22	Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. <i>Cancer Causes and Control</i> , 2003, 14, 805-814.	1.8	299
23	Epidemiology of HPV infection among Mexican women with normal cervical cytology. <i>International Journal of Cancer</i> , 2001, 91, 412-420.	5.1	277
24	Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1444-1451.	6.3	274
25	Oral cancer in southern India: The influence of smoking, drinking, paan-chewing and oral hygiene. <i>International Journal of Cancer</i> , 2002, 98, 440-445.	5.1	258
26	Oral Human Papillomavirus in Healthy Individuals: A Systematic Review of the Literature. <i>Sexually Transmitted Diseases</i> , 2010, 37, 386-391.	1.7	249
27	An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2019, 111, 923-932.	6.3	249
28	Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. <i>Lancet Oncology</i> , The, 2015, 16, 775-786.	10.7	247
29	Human Papillomavirus Infection with Multiple Types: Pattern of Coinfection and Risk of Cervical Disease. <i>Journal of Infectious Diseases</i> , 2011, 203, 910-920.	4.0	245
30	14-day triple, 5-day concomitant, and 10-day sequential therapies for <i>Helicobacter pylori</i> infection in seven Latin American sites: a randomised trial. <i>Lancet</i> , The, 2011, 378, 507-514.	13.7	239
31	Human Papillomavirus Infection and Cervical Cancer in Latin America. <i>New England Journal of Medicine</i> , 1989, 320, 1437-1441.	27.0	229
32	A Population-Based Prospective Study of Carcinogenic Human Papillomavirus Variant Lineages, Viral Persistence, and Cervical Neoplasia. <i>Cancer Research</i> , 2010, 70, 3159-3169.	0.9	221
33	Cigarette, Cigar, and Pipe Smoking and the Risk of Head and Neck Cancers: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. <i>American Journal of Epidemiology</i> , 2013, 178, 679-690.	3.4	220
34	The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. <i>International Journal of Cancer</i> , 2004, 108, 741-749.	5.1	219
35	<i>Chlamydia trachomatis</i> and invasive cervical cancer: A pooled analysis of the IARC multicentric case-control study. <i>International Journal of Cancer</i> , 2004, 111, 431-439.	5.1	218
36	Evidence for <i>Chlamydia trachomatis</i> as a Human Papillomavirus Cofactor in the Etiology of Invasive Cervical Cancer in Brazil and the Philippines. <i>Journal of Infectious Diseases</i> , 2002, 185, 324-331.	4.0	210

#	ARTICLE	IF	CITATIONS
37	Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. <i>International Journal of Epidemiology</i> , 2010, 39, 182-196.	1.9	210
38	Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. <i>Journal of Experimental Medicine</i> , 2005, 201, 1069-1075.	8.5	209
39	CIN2 Is a Much Less Reproducible and Less Valid Diagnosis than CIN3. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 441-446.	1.4	200
40	Utility of liquid-based cytology for cervical carcinoma screening. <i>Cancer</i> , 1999, 87, 48-55.	4.1	199
41	Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. <i>Cancer Prevention Research</i> , 2013, 6, 1242-1250.	1.5	185
42	Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 1997, 1, 362-375.	1.1	183
43	Risk Factors for Cervical Cancer in Thailand: a Case-Control Study. <i>Journal of the National Cancer Institute</i> , 1998, 90, 50-57.	6.3	179
44	Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 324-327.	2.5	177
45	Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. <i>The Lancet Global Health</i> , 2015, 3, e85-e94.	6.3	177
46	Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries. <i>Lancet, The</i> , 2017, 389, 861-870.	13.7	171
47	Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. <i>Lancet Oncology, The</i> , 2011, 12, 862-870.	10.7	168
48	Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. <i>BMJ: British Medical Journal</i> , 2009, 339, b2569-b2569.	2.3	167
49	Present status of human papillomavirus vaccine development and implementation. <i>Lancet Oncology, The</i> , 2015, 16, e206-e216.	10.7	165
50	Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. <i>Nature Genetics</i> , 2016, 48, 1544-1550.	21.4	164
51	Sexual Behavior, Condom Use, and Human Papillomavirus: Pooled Analysis of the IARC Human Papillomavirus Prevalence Surveys. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 326-333.	2.5	163
52	The Oral Cavity Contains Abundant Known and Novel Human Papillomaviruses From the Betapapillomavirus and Gammapapillomavirus Genera. <i>Journal of Infectious Diseases</i> , 2011, 204, 787-792.	4.0	162
53	Comparisons of HPV DNA detection by MY09/11 PCR methods. <i>Journal of Medical Virology</i> , 2002, 68, 417-423.	5.0	158
54	A Genome-Wide Association Study of Upper Aerodigestive Tract Cancers Conducted within the INHANCE Consortium. <i>PLoS Genetics</i> , 2011, 7, e1001333.	3.5	158

#	ARTICLE	IF	CITATIONS
55	Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1653-1662.	6.3	155
56	PARITY AS A RISK FACTOR FOR CERVICAL CANCER. <i>American Journal of Epidemiology</i> , 1989, 130, 486-496.	3.4	152
57	Cervicovaginal microbiome and natural history of HPV in a longitudinal study. <i>PLoS Pathogens</i> , 2020, 16, e1008376.	4.7	150
58	Diversifying Selection in Human Papillomavirus Type 16 Lineages Based on Complete Genome Analyses. <i>Journal of Virology</i> , 2005, 79, 7014-7023.	3.4	148
59	Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. <i>Vaccine</i> , 2008, 26, 4795-4808.	3.8	145
60	Total Exposure and Exposure Rate Effects for Alcohol and Smoking and Risk of Head and Neck Cancer: A Pooled Analysis of Case-Control Studies. <i>American Journal of Epidemiology</i> , 2009, 170, 937-947.	3.4	143
61	Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica. <i>Cancer Discovery</i> , 2011, 1, 408-419.	9.4	143
62	Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. <i>International Journal of Epidemiology</i> , 2008, 37, 536-546.	1.9	141
63	Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. <i>PLoS ONE</i> , 2011, 6, e20183.	2.5	137
64	The fight against gastric cancer – the IARC Working Group report. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 1107-1114.	2.4	135
65	High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. <i>International Journal of Cancer</i> , 2007, 121, 2787-2793.	5.1	134
66	World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 132, 252-258.	2.3	134
67	Sexual behavior, venereal diseases, hygiene practices, and invasive cervical cancer in a high-risk population. <i>Cancer</i> , 1990, 65, 380-386.	4.1	131
68	Population-Based Human Papillomavirus Prevalence in Lampang and Songkla, Thailand. <i>Journal of Infectious Diseases</i> , 2003, 187, 1246-1256.	4.0	130
69	HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. <i>Vaccine</i> , 2011, 29, 2011-2014.	3.8	130
70	A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests. <i>Journal of the National Cancer Institute</i> , 2005, 97, 147-150.	6.3	128
71	Risk factors for head and neck cancer in young adults: a pooled analysis in the INHANCE consortium. <i>International Journal of Epidemiology</i> , 2015, 44, 169-185.	1.9	128
72	Human papillomavirus and risk factors for cervical cancer in Chennai, India: A case-control study. <i>International Journal of Cancer</i> , 2003, 107, 127-133.	5.1	126

#	ARTICLE	IF	CITATIONS
73	Cervical Human Papillomavirus Infection in the Female Population in Barcelona, Spain. Sexually Transmitted Diseases, 2003, 30, 788-793.	1.7	126
74	Human papillomavirus infection among women in South and North Vietnam. International Journal of Cancer, 2003, 104, 213-220.	5.1	124
75	Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. International Journal of Cancer, 2013, 132, 1412-1422.	5.1	123
76	Family history of cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. International Journal of Cancer, 2009, 124, 394-401.	5.1	122
77	Reproductive Factors, Oral Contraceptive Use, and Human Papillomavirus Infection: Pooled Analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2148-2153.	2.5	118
78	Prevalence of human papillomavirus infection in women in Busan, South Korea. International Journal of Cancer, 2003, 103, 413-421.	5.1	116
79	Diet and the risk of head and neck cancer: a pooled analysis in the INHANCE consortium. Cancer Causes and Control, 2012, 23, 69-88.	1.8	116
80	Human papillomavirus infection and oral cancer: A case-control study in Montreal, Canada. Oral Oncology, 2008, 44, 242-250.	1.5	113
81	Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. International Journal of Cancer, 2015, 136, 1125-1139.	5.1	112
82	The male factor in the etiology of cervical cancer among sexually monogamous women. International Journal of Cancer, 1989, 44, 199-203.	5.1	111
83	Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. American Journal of Obstetrics and Gynecology, 2016, 215, 212.e1-212.e15.	1.3	108
84	Oral Contraceptive Use and Risk of Invasive Cervical Cancer. International Journal of Epidemiology, 1990, 19, 4-11.	1.9	107
85	Common Variants in Immune and DNA Repair Genes and Risk for Human Papillomavirus Persistence and Progression to Cervical Cancer. Journal of Infectious Diseases, 2009, 199, 20-30.	4.0	107
86	Prevention Strategies for Gastric Cancer: A Global Perspective. Clinical Endoscopy, 2014, 47, 478.	1.5	107
87	Relationships of Human Papillomavirus Type, Qualitative Viral Load, and Age with Cytologic Abnormality. Cancer Research, 2006, 66, 10112-10119.	0.9	105
88	Common Genetic Variants and Risk for HPV Persistence and Progression to Cervical Cancer. PLoS ONE, 2010, 5, e8667.	2.5	104
89	Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies. Vaccine, 2018, 36, 4774-4782.	3.8	103
90	Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes and Control, 2013, 24, 209-215.	1.8	102

#	ARTICLE	IF	CITATIONS
91	Concurrent Infection with Multiple Human Papillomavirus Types: Pooled Analysis of the IARC HPV Prevalence Surveys. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 503-510.	2.5	101
92	The Cervical Microbiome over 7 Years and a Comparison of Methodologies for Its Characterization. <i>PLoS ONE</i> , 2012, 7, e40425.	2.5	101
93	A Case-Control Study of Nutrient Status and Invasive Cervical Cancer. <i>American Journal of Epidemiology</i> , 1991, 134, 1335-1346.	3.4	100
94	Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. <i>Cancer</i> , 1997, 81, 89-97.	4.1	99
95	Human papillomavirus infection and invasive cervical cancer in Paraguay. <i>International Journal of Cancer</i> , 2000, 85, 486-491.	5.1	99
96	Methylation of Human Papillomavirus Type 16 Genome and Risk of Cervical Precancer in a Costa Rican Population. <i>Journal of the National Cancer Institute</i> , 2012, 104, 556-565.	6.3	99
97	Human Papillomavirus Type 16 and TP53 Mutation in Oral Cancer. <i>Cancer Research</i> , 2004, 64, 468-471.	0.9	98
98	Persistent Human Papillomavirus Infection Is Associated with a Generalized Decrease in Immune Responsiveness in Older Women. <i>Cancer Research</i> , 2006, 66, 11070-11076.	0.9	98
99	Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. <i>Lancet Oncology</i> , The, 2011, 12, 1023-1031.	10.7	98
100	Human Papillomavirus (HPV) Vaccines: Limited Cross-Protection against Additional HPV Types. <i>Journal of Infectious Diseases</i> , 2009, 199, 919-922.	4.0	97
101	A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. <i>BMC Infectious Diseases</i> , 2012, 12, 33.	2.9	96
102	Age-Related Changes of the Cervix Influence Human Papillomavirus Type Distribution. <i>Cancer Research</i> , 2006, 66, 1218-1224.	0.9	95
103	Human Leukocyte Antigen Class I and II Alleles and Risk of Cervical Neoplasia: Results from a Population-Based Study in Costa Rica. <i>Journal of Infectious Diseases</i> , 2001, 184, 1310-1314.	4.0	94
104	Gastric cancer incidence and mortality is associated with altitude in the mountainous regions of Pacific Latin America. <i>Cancer Causes and Control</i> , 2013, 24, 249-256.	1.8	94
105	Prevalence of Human Papillomavirus Infection Among Women in Concordia, Argentina. <i>Sexually Transmitted Diseases</i> , 2003, 30, 593-599.	1.7	93
106	Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. <i>Vaccine</i> , 2014, 32, 5087-5097.	3.8	92
107	Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv302.	6.3	92
108	Body mass index and risk of head and neck cancer in a pooled analysis of case-control studies in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium. <i>International Journal of Epidemiology</i> , 2010, 39, 1091-1102.	1.9	89

#	ARTICLE	IF	CITATIONS
109	Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. Journal of the National Cancer Institute, 2020, 112, 1038-1046.	6.3	89
110	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
111	An Updated Natural History Model of Cervical Cancer: Derivation of Model Parameters. American Journal of Epidemiology, 2014, 180, 545-555.	3.4	87
112	Type of Alcoholic Beverage and Risk of Head and Neck Cancer—A Pooled Analysis Within the INHANCE Consortium. American Journal of Epidemiology, 2009, 169, 132-142.	3.4	85
113	A Case-Control Study of Nutrient Status and Invasive Cervical Cancer. American Journal of Epidemiology, 1991, 134, 1347-1355.	3.4	82
114	Evolutionary Dynamics of Variant Genomes of Human Papillomavirus Types 18, 45, and 97. Journal of Virology, 2009, 83, 1443-1455.	3.4	82
115	Prevention of Gastric Cancer. JAMA - Journal of the American Medical Association, 2014, 312, 1197.	7.4	82
116	The epidemiology of <i>Helicobacter pylori</i> infection in Europe and the impact of lifestyle on its natural evolution toward stomach cancer after infection: A systematic review. Helicobacter, 2018, 23, e12483.	3.5	81
117	Behavioral/Lifestyle and Immunologic Factors Associated with HPV Infection among Women Older Than 45 Years. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 3044-3054.	2.5	80
118	Screening for Cervical Cancer in Latin America: A Case-Control Study. International Journal of Epidemiology, 1992, 21, 1050-1056.	1.9	79
119	Chlamydia trachomatis Infection in Female Partners of Circumcised and Uncircumcised Adult Men. American Journal of Epidemiology, 2005, 162, 907-916.	3.4	79
120	Geographic Variation in the Prevalence of Kaposi Sarcoma—Associated Herpesvirus and Risk Factors for Transmission. Journal of Infectious Diseases, 2009, 199, 1449-1456.	4.0	79
121	Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine, 2014, 32, 725-732.	3.8	79
122	Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ: British Medical Journal, 2010, 340, c712-c712.	2.3	78
123	Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine, 2008, 26, 3608-3616.	3.8	77
124	Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern humans. PLoS Pathogens, 2018, 14, e1007352.	4.7	77
125	High Prevalence of Human Papillomavirus Infection in Mexican Males. Sexually Transmitted Diseases, 2001, 28, 277-280.	1.7	75
126	Comparison of Two PCR-Based Human Papillomavirus Genotyping Methods. Journal of Clinical Microbiology, 2008, 46, 3437-3445.	3.9	75

#	ARTICLE	IF	CITATIONS
127	Comparison of the SPF ₁₀ -LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1447-1454.	3.9	74
128	Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10 000 women in Guanacaste, Costa Rica. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2004, 15, 75-89.	1.1	74
129	Diet and body mass, and oral and oropharyngeal squamous cell carcinomas: Analysis from the IARC multinational case-control study. <i>International Journal of Cancer</i> , 2006, 118, 2293-2297.	5.1	73
130	A Comparison of Cervical and Vaginal Human Papillomavirus. <i>Sexually Transmitted Diseases</i> , 2007, 34, 849-855.	1.7	73
131	A Population-Based Study of Vaginal Human Papillomavirus Infection in Hysterectomized Women. <i>Journal of Infectious Diseases</i> , 2004, 190, 458-467.	4.0	72
132	Risk of Recurrent <i>Helicobacter pylori</i> Infection 1 Year After Initial Eradication Therapy in 7 Latin American Communities. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 578.	7.4	72
133	Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 205-212.	6.3	71
134	Sequence Imputation of HPV16 Genomes for Genetic Association Studies. <i>PLoS ONE</i> , 2011, 6, e21375.	2.5	70
135	Adult height and head and neck cancer: a pooled analysis within the INHANCE Consortium. <i>European Journal of Epidemiology</i> , 2014, 29, 35-48.	5.7	66
136	Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. <i>Lancet Oncology</i> , The, 2015, 16, e226-e233.	10.7	66
137	Risk Factors for Cervical Cancer by Histology. <i>Gynecologic Oncology</i> , 1993, 51, 301-306.	1.4	65
138	Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration. <i>British Journal of Cancer</i> , 2020, 123, 1456-1463.	6.4	65
139	Elevated Systemic Levels of Inflammatory Cytokines in Older Women with Persistent Cervical Human Papillomavirus Infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1954-1959.	2.5	64
140	Smoking and Passive Smoking in Cervical Cancer Risk: Pooled Analysis of Couples from the IARC Multicentric Case-control Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1379-1390.	2.5	64
141	Enhanced Enzyme-Linked Immunosorbent Assay for Detection of Antibodies to Virus-Like Particles of Human Papillomavirus. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1755-1760.	3.9	63
142	<i>Chlamydia trachomatis</i> and Risk of Prevalent and Incident Cervical Premalignancy in a Population-Based Cohort. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1794-1804.	6.3	63
143	Body Mass Index, Cigarette Smoking, and Alcohol Consumption and Cancers of the Oral Cavity, Pharynx, and Larynx: Modeling Odds Ratios in Pooled Case-Control Data. <i>American Journal of Epidemiology</i> , 2010, 171, 1250-1261.	3.4	63
144	Invasive Cervical Cancer and Smoking in Latin America. <i>Journal of the National Cancer Institute</i> , 1989, 81, 205-211.	6.3	61

#	ARTICLE	IF	CITATIONS
145	Comprehensive Analysis of Human Leukocyte Antigen Class I Alleles and Cervical Neoplasia in 3 Epidemiologic Studies. <i>Journal of Infectious Diseases</i> , 2002, 186, 598-605.	4.0	59
146	Cervical carcinoma in Algiers, Algeria: Human papillomavirus and lifestyle risk factors. <i>International Journal of Cancer</i> , 2005, 113, 483-489.	5.1	59
147	HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. <i>International Journal of Cancer</i> , 2005, 115, 329-332.	5.1	59
148	Cervical cancer in Central and South America: Burden of disease and status of disease control. <i>Cancer Epidemiology</i> , 2016, 44, S121-S130.	1.9	59
149	Human papillomavirus (HPV) types 101 and 103 isolated from cervicovaginal cells lack an E6 open reading frame (ORF) and are related to gamma-papillomaviruses. <i>Virology</i> , 2007, 360, 447-453.	2.4	58
150	Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 1394-9.	2.5	57
151	Cervicography screening for cervical cancer among 8460 women in a high-risk population. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 180, 290-298.	1.3	56
152	Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study. <i>The Lancet Global Health</i> , 2019, 7, e772-e783.	6.3	56
153	A Competitive Serological Assay Shows Naturally Acquired Immunity to Human Papillomavirus Infections in the Guanacaste Natural History Study. <i>Journal of Infectious Diseases</i> , 2011, 204, 94-102.	4.0	55
154	Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. <i>Lancet Oncology</i> , The, 2020, 21, 1643-1652.	10.7	54
155	Multicentric randomised study of <i>Helicobacter pylori</i> eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study. <i>BMJ Open</i> , 2017, 7, e016999.	1.9	53
156	Epidemiologic determinants of vaginal pH. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 180, 1060-1066.	1.3	52
157	The Natural History of Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia Among Young Women in the Guanacaste Cohort Shortly After Initiation of Sexual Life. <i>Sexually Transmitted Diseases</i> , 2007, 34, 494-502.	1.7	51
158	Human Papillomavirus Types by Age in Cervical Cancer Precursors: Predominance of Human Papillomavirus 16 in Young Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 863-865.	2.5	51
159	Prevalence of and Risk Factors for Anal Human Papillomavirus Infection Among Young Healthy Women in Costa Rica. <i>Journal of Infectious Diseases</i> , 2012, 206, 1103-1110.	4.0	51
160	Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer. <i>International Journal of Cancer</i> , 2014, 135, 2453-2461.	5.1	51
161	Clustering of Multiple Human Papillomavirus Infections in Women From a Population-Based Study in Guanacaste, Costa Rica. <i>Journal of Infectious Diseases</i> , 2011, 204, 385-390.	4.0	50
162	Stability of archived liquid-based cervical cytologic specimens. <i>Cancer</i> , 2003, 99, 89-96.	4.1	49

#	ARTICLE	IF	CITATIONS
163	An examination of male and female odds ratios by BMI, cigarette smoking, and alcohol consumption for cancers of the oral cavity, pharynx, and larynx in pooled data from 15 case-control studies. <i>Cancer Causes and Control</i> , 2011, 22, 1217-1231.	1.8	48
164	Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®. <i>Vaccine</i> , 2012, 31, 165-170.	3.8	48
165	Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. <i>Journal of Immunological Methods</i> , 1999, 225, 131-143.	1.4	47
166	Long-Term Persistence of Prevalently Detected Human Papillomavirus Infections in the Absence of Detectable Cervical Precancer and Cancer. <i>Journal of Infectious Diseases</i> , 2011, 203, 814-822.	4.0	47
167	Prevalence of and Risk Factors for Oral Human Papillomavirus Among Young Women in Costa Rica. <i>Journal of Infectious Diseases</i> , 2013, 208, 1643-1652.	4.0	47
168	Evolution and Taxonomic Classification of Alphapapillomavirus 7 Complete Genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70. <i>PLoS ONE</i> , 2013, 8, e72565.	2.5	47
169	Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the International Agency for Research on Cancer HPV Prevalence Surveys. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2379-2388.	2.5	46
170	Recommendations for Cervical Cancer Prevention in Latin America and the Caribbean. <i>Vaccine</i> , 2008, 26, L96-L107.	3.8	44
171	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw300.	6.3	43
172	Systematic reviews as a "lens of evidence": Determinants of benefits and harms of breast cancer screening. <i>International Journal of Cancer</i> , 2019, 145, 994-1006.	5.1	43
173	Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 2271-6.	2.5	43
174	Prevalence and Risk Factors for Herpes Simplex Virus Type 2 Infection Among Middle-Age Women in Brazil and the Philippines. <i>Sexually Transmitted Diseases</i> , 2001, 28, 187-194.	1.7	42
175	Cervical Infection With <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> in Women From Ten Areas in Four Continents. <i>Sexually Transmitted Diseases</i> , 2007, 34, 563-569.	1.7	42
176	Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1030-1037.	6.3	42
177	Integration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the Caribbean. <i>Vaccine</i> , 2008, 26, L88-L95.	3.8	40
178	Low frequency of cigarette smoking and the risk of head and neck cancer in the INHANCE consortium pooled analysis. <i>International Journal of Epidemiology</i> , 2016, 45, 835-845.	1.9	40
179	Correlates of IL-10 and IL-12 concentrations in cervical secretions. <i>Journal of Clinical Immunology</i> , 2003, 23, 175-183.	3.8	39
180	HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays. <i>PLoS ONE</i> , 2013, 8, e53067.	2.5	39

#	ARTICLE	IF	CITATIONS
181	A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 477-84.	2.5	39
182	Quantitative Detection and Genotyping of <i>Helicobacter pylori</i> from Stool using Droplet Digital PCR Reveals Variation in Bacterial Loads that Correlates with <i>cagA</i> Virulence Gene Carriage. <i>Helicobacter</i> , 2016, 21, 325-333.	3.5	37
183	Single Nucleotide Polymorphisms in the PRDX3 and RPS19 and Risk of HPV Persistence and Cervical Precancer/Cancer. <i>PLoS ONE</i> , 2012, 7, e33619.	2.5	37
184	Implementation of HPV testing for cervical cancer screening in programmatic contexts: The Jujuy demonstration project in Argentina. <i>International Journal of Cancer</i> , 2015, 137, 1709-1718.	5.1	36
185	Prevalence of and Associated Risk Factors for High Risk Human Papillomavirus among Sexually Active Women, Swaziland. <i>PLoS ONE</i> , 2017, 12, e0170189.	2.5	36
186	Injectable contraceptives and risk of invasive cervical cancer: Evidence of an association. <i>International Journal of Cancer</i> , 1990, 46, 5-7.	5.1	35
187	Performance of a semiautomated papanicolaou smear screening system. <i>Cancer</i> , 1998, 84, 273-280.	4.1	35
188	Innovations in understanding the biology of cervical cancer. <i>Cancer</i> , 2003, 98, 2064-2069.	4.1	35
189	New Approaches to Cervical Cancer Screening in Latin America and the Caribbean. <i>Vaccine</i> , 2008, 26, L49-L58.	3.8	35
190	Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1399-1406.	3.3	35
191	Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). <i>Virology</i> , 2018, 516, 86-101.	2.4	35
192	Determinants of seropositivity among HPV-16/18 DNA positive young women. <i>BMC Infectious Diseases</i> , 2010, 10, 238.	2.9	34
193	European Code against Cancer 4th Edition: Infections and Cancer. <i>Cancer Epidemiology</i> , 2015, 39, S120-S138.	1.9	34
194	Comparison of Ophthalmic Sponges for Measurements of Immune Markers from Cervical Secretions. <i>Vaccine Journal</i> , 2004, 11, 399-405.	3.1	33
195	EUROGIN 2008 roadmap on cervical cancer prevention. <i>International Journal of Cancer</i> , 2009, 125, 2246-2255.	5.1	33
196	Persistence of Concurrent Infections with Multiple Human Papillomavirus Types: A Population-based Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 823-827.	4.0	33
197	Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. <i>BMJ</i> , The, 2015, 351, h4358.	6.0	32
198	Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: A bivariate spline model approach. <i>Oral Oncology</i> , 2019, 94, 47-57.	1.5	32

#	ARTICLE	IF	CITATIONS
199	Human Papillomavirus Vaccine Should Be Given before Sexual Debut for Maximum Benefit. <i>Journal of Infectious Diseases</i> , 2007, 196, 1431-1432.	4.0	31
200	Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 30-38.	3.3	31
201	Lessons learned from the INHANCE consortium: An overview of recent results on head and neck cancer. <i>Oral Diseases</i> , 2021, 27, 73-93.	3.0	31
202	The relations between cervical cancer and serological markers of nutritional status. <i>Nutrition and Cancer</i> , 1994, 21, 193-201.	2.0	30
203	Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia. <i>International Journal of Cancer</i> , 2001, 94, 520-526.	5.1	30
204	Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. <i>International Journal of Cancer</i> , 2012, 131, 211-218.	5.1	29
205	Low risk of type-specific carcinogenic HPV re-appearence with subsequent cervical intraepithelial neoplasia grade 2/3. <i>International Journal of Cancer</i> , 2012, 131, 1874-1881.	5.1	29
206	Location and Density of Immune Cells in Precursor Lesions and Cervical Cancer. <i>Cancer Microenvironment</i> , 2013, 6, 69-77.	3.1	28
207	Seroprevalence and Correlates of Human Papillomavirus 16/18 Seropositivity Among Young Women in Costa Rica. <i>Sexually Transmitted Diseases</i> , 2010, 37, 706-714.	1.7	27
208	Vitamin or mineral supplement intake and the risk of head and neck cancer: pooled analysis in the INHANCE consortium. <i>International Journal of Cancer</i> , 2012, 131, 1686-1699.	5.1	27
209	Genetic Variants in Nicotine Addiction and Alcohol Metabolism Genes, Oral Cancer Risk and the Propensity to Smoke and Drink Alcohol: A Replication Study in India. <i>PLoS ONE</i> , 2014, 9, e88240.	2.5	27
210	Impact of Human Papillomavirus Vaccination on Cervical Cytology Screening, Colposcopy, and Treatment. <i>American Journal of Epidemiology</i> , 2013, 178, 752-760.	3.4	26
211	Evaluation of a Novel PCR-Based Assay for Detection and Identification of <i>Chlamydia trachomatis</i> Serovars in Cervical Specimens. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3986-3991.	3.9	25
212	Factors Associated with Fluctuations in IgA and IgG Levels at the Cervix during the Menstrual Cycle. <i>Journal of Infectious Diseases</i> , 2009, 199, 455-463.	4.0	25
213	Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia. <i>Cancer Prevention Research</i> , 2016, 9, 766-771.	1.5	25
214	Family history as a co-factor for adenocarcinoma and squamous cell carcinoma of the uterine cervix: Results from two studies conducted in Costa Rica and the United States. <i>International Journal of Cancer</i> , 2005, 116, 599-605.	5.1	24
215	Direct Comparison of HPV16 Serological Assays Used to Define HPV-Naïve Women in HPV Vaccine Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1547-1554.	2.5	24
216	Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju400-dju400.	6.3	24

#	ARTICLE	IF	CITATIONS
217	Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays. <i>Frontiers in Oncology</i> , 2014, 3, 328.	2.8	24
218	Common Genetic Variation in <i>TP53</i> and Risk of Human Papillomavirus Persistence and Progression to CIN3/Cancer Revisited. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1631-1637.	2.5	23
219	Immunosuppression in cervical cancer with special reference to arginase activity. <i>Gynecologic Oncology</i> , 2014, 135, 74-80.	1.4	23
220	Type-Specific Seroprevalence of Herpes Simplex Virus Type 2 and Associated Risk Factors in Middle-Aged Women From 6 Countries: The IARC Multicentric Study. <i>Sexually Transmitted Diseases</i> , 2007, 34, 1019-1024.	1.7	23
221	Management of <i>Helicobacter pylori</i> infection in Latin America: A Delphi technique-based consensus. <i>World Journal of Gastroenterology</i> , 2014, 20, 10969.	3.3	23
222	Can cervicography be improved? An evaluation with arbitrated cervicography interpretations. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 187, 15-23.	1.3	22
223	Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. <i>BMC Infectious Diseases</i> , 2014, 14, 120.	2.9	22
224	Identification and characterization of two novel human papillomaviruses (HPVs) by overlapping PCR: HPV102 and HPV106. <i>Journal of General Virology</i> , 2007, 88, 2952-2955.	2.9	21
225	Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country. <i>International Journal of Cancer</i> , 2021, 148, 1383-1393.	5.1	21
226	Recent progress in gastric cancer prevention. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 50-51, 101733.	2.4	21
227	molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history. <i>Nature Communications</i> , 2022, 13, 233.	12.8	20
228	Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 818-828.	6.3	19
229	Epidemiology of Genital Chlamydia trachomatis Infection Among Young Women in Costa Rica. <i>Sexually Transmitted Diseases</i> , 2008, 35, 461-468.	1.7	18
230	Evaluation of the Polyclonal ELISA HPV Serology Assay as a Biomarker for Human Papillomavirus Exposure. <i>Sexually Transmitted Diseases</i> , 2011, 38, 976-982.	1.7	18
231	Switch from cytology-based to human papillomavirus test-based cervical screening: Implications for colposcopy. <i>International Journal of Cancer</i> , 2012, 130, 1879-1887.	5.1	18
232	Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. <i>Journal of Infectious Diseases</i> , 2016, 213, 939-947.	4.0	18
233	Evaluation of the FTA Carrier Device for Human Papillomavirus Testing in Developing Countries. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3870-3876.	3.9	17
234	<i>Helicobacter pylori</i> Eradication in the Prevention of Gastric Cancer: Are More Trials Needed?. <i>Current Oncology Reports</i> , 2013, 15, 517-525.	4.0	17

#	ARTICLE	IF	CITATIONS
235	Reduced Prevalence of Vulvar HPV16/18 Infection Among Women Who Received the HPV16/18 Bivalent Vaccine: A Nested Analysis Within the Costa Rica Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1890-1899.	4.0	17
236	Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. <i>Vaccine</i> , 2015, 33, 2141-2151.	3.8	17
237	Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. <i>Journal of Infectious Diseases</i> , 2019, 220, 1609-1619.	4.0	17
238	Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol. <i>BMJ Open</i> , 2020, 10, e035796.	1.9	17
239	Using Prior Information from the Medical Literature in GWAS of Oral Cancer Identifies Novel Susceptibility Variant on Chromosome 4 - the AdAPT Method. <i>PLoS ONE</i> , 2012, 7, e36888.	2.5	17
240	Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. <i>Sexually Transmitted Diseases</i> , 2007, 34, 1019-24.	1.7	17
241	Identification of a novel human papillomavirus (HPV97) related to HPV18 and HPV45. <i>International Journal of Cancer</i> , 2007, 121, 193-198.	5.1	16
242	Infection with Human Papilloma Virus (HPV) and risk of subsites within the oral cancer. <i>Cancer Epidemiology</i> , 2021, 75, 102020.	1.9	16
243	Genetic Admixture and Population Substructure in Guanacaste Costa Rica. <i>PLoS ONE</i> , 2010, 5, e13336.	2.5	16
244	A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 815-23.	2.5	16
245	Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. <i>International Journal of Cancer</i> , 2009, 125, 1649-1656.	5.1	15
246	Treatability by Cryotherapy in a Screen-and-Treat Strategy. <i>Journal of Lower Genital Tract Disease</i> , 2009, 13, 174-181.	1.9	15
247	Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial. <i>Vaccine</i> , 2022, 40, 76-88.	3.8	15
248	A Sex-Specific Association between a 15q25 Variant and Upper Aerodigestive Tract Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 658-664.	2.5	14
249	Effect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates. <i>American Journal of Epidemiology</i> , 2014, 180, 599-607.	3.4	14
250	Socio-demographic and reproductive determinants of cervical neoplasia in seven sub-Saharan African countries. <i>Cancer Causes and Control</i> , 2016, 27, 1437-1446.	1.8	14
251	T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study. <i>PLoS ONE</i> , 2018, 13, e0178167.	2.5	14
252	Effect of vaccination against oral HPV-16 infection in high school students in the city of Cali, Colombia. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 7, 112-117.	4.5	14

#	ARTICLE	IF	CITATIONS
253	Factors associated with high-risk human papillomavirus infection and high-grade cervical neoplasia: A population-based study in Paraguay. <i>PLoS ONE</i> , 2019, 14, e0218016.	2.5	13
254	Performance of an HPV 16/18 E6 oncoprotein test for detection of cervical precancer and cancer. <i>International Journal of Cancer</i> , 2019, 145, 2042-2050.	5.1	13
255	Psycho-social impact of positive human papillomavirus testing in Jujuy, Argentina results from the Psycho-Estampa study. <i>Preventive Medicine Reports</i> , 2020, 18, 101070.	1.8	13
256	Cognitions and behaviours of general practitioners in France regarding HPV vaccination: A theory-based systematic review. <i>Preventive Medicine</i> , 2021, 143, 106323.	3.4	13
257	Collection of Cervical Secretions Does Not Adversely Affect Pap Smears Taken Immediately Afterward. <i>Vaccine Journal</i> , 1998, 5, 491-493.	2.6	13
258	Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine. <i>Contemporary Clinical Trials</i> , 2018, 68, 35-44.	1.8	12
259	Accuracy of two plasma antibody tests and faecal antigen test for non-invasive detection of <i>H. pylori</i> in middle-aged Caucasian general population sample. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 777-783.	1.5	12
260	Age at start of using tobacco on the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium (INHANCE). <i>Cancer Epidemiology</i> , 2019, 63, 101615.	1.9	12
261	Regional variations in <i>Helicobacter pylori</i> infection, gastric atrophy and gastric cancer risk: The ENIGMA study in Chile. <i>PLoS ONE</i> , 2020, 15, e0237515.	2.5	12
262	Preparing Digitized Cervigrams for Colposcopy Research and Education: Determination of Optimal Resolution and Compression Parameters. <i>Journal of Lower Genital Tract Disease</i> , 2006, 10, 39-44.	1.9	11
263	Lack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties. <i>Archives of Virology</i> , 2010, 155, 367-370.	2.1	11
264	Establishment and Operation of a Biorepository for Molecular Epidemiologic Studies in Costa Rica. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 916-922.	2.5	11
265	Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. <i>Vaccine</i> , 2020, 38, 5997-6006.	3.8	11
266	Determinants and Correlation of Systemic and Cervical Concentrations of Total IgA and IgG. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2672-2676.	2.5	10
267	Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18-year follow-up of the Guanacaste cohort. <i>International Journal of Cancer</i> , 2017, 140, 1926-1934.	5.1	10
268	The Natural History of Oral Human Papillomavirus in Young Costa Rican Women. <i>Sexually Transmitted Diseases</i> , 2017, 44, 442-449.	1.7	10
269	Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer. <i>Nature Communications</i> , 2021, 12, 5945.	12.8	10
270	Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 1449-56.	2.5	10

#	ARTICLE	IF	CITATIONS
271	Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination. <i>Journal of Infectious Diseases</i> , 2019, 219, 41-49.	4.0	9
272	Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium. <i>Oral Diseases</i> , 2023, 29, 1565-1578.	3.0	9
273	Stability of archived liquid-based cytologic specimens. <i>Cancer</i> , 2003, 99, 320-322.	4.1	8
274	Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels. <i>Frontiers in Oncology</i> , 2012, 2, 61.	2.8	8
275	Population preferences for breast cancer screening policies: Discrete choice experiment in Belarus. <i>PLoS ONE</i> , 2019, 14, e0224667.	2.5	8
276	Reproducibility, Temporal Variability, and Concordance of Serum and Fecal Bile Acids and Short Chain Fatty Acids in a Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1875-1883.	2.5	8
277	Performance of Direct Visual Inspection of the Cervix with Acetic Acid and Magnification in a Previously Screened Population. <i>Journal of Lower Genital Tract Disease</i> , 2004, 8, 132-138.	1.9	7
278	Alterations of Tâ€œcell surface markers in older women with persistent human papillomavirus infection. <i>International Journal of Cancer</i> , 2011, 128, 597-607.	5.1	7
279	Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2965-2974.	3.3	7
280	Hepatitis C virus seroprevalence in the general female population from 8 countries. <i>Journal of Clinical Virology</i> , 2015, 68, 89-93.	3.1	7
281	Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 1576-1581.	4.0	7
282	Prevalence of Atrophic Gastritis in Kazakhstan and the Accuracy of Pepsinogen Tests to Detect Gastric Mucosal Atrophy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 3825-3829.	1.2	7
283	Who Could Be Blamed in the Case of Discrepant Histology and Serology Results for <i>Helicobacter pylori</i> Detection?. <i>Diagnostics</i> , 2022, 12, 133.	2.6	7
284	An Evaluation by Midwives and Gynecologists of Treatability of Cervical Lesions by Cryotherapy Among Human Papillomavirus-Positive Women. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 728-733.	2.5	6
285	Toward the World Code Against Cancer. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	6
286	Prevalence and Potential Risk Factors of <i>Helicobacter pylori</i> Infection among Asymptomatic Individuals in Kazakhstan. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 597-602.	1.2	6
287	Codetection of a Mixed Population ofcandHPV62 Containing Wildâ€™Type and Disrupted E1 Openâ€™Reading Frame in a 45â€™Yearâ€™Old Woman with Normal Cytology. <i>Journal of Infectious Diseases</i> , 2004, 190, 1303-1309.	4.0	5
288	Longitudinal Analysis of Carcinogenic Human Papillomavirus Infection and Associated Cytologic Abnormalities in the Guanacaste Natural History Study: Looking Ahead to Cotesting. <i>Journal of Infectious Diseases</i> , 2012, 205, 498-505.	4.0	5

#	ARTICLE	IF	CITATIONS
289	Comparison of immediate colposcopy, repeat conventional cytology and high-risk human papillomavirus testing for the clinical management of atypical squamous cells of undetermined significance cytology in routine health services of Medellín, Colombia: The <sc>ASCUS</sc> trial. <i>International Journal of Cancer</i> , 2021, 148, 1394-1407.	5.1	5
290	Different human papillomavirus types share early natural history transitions in immunocompetent women. <i>International Journal of Cancer</i> , 2022, 151, 920-929.	5.1	5
291	Herpes Simplex Virus Type-2 Seropositivity Among Ever Married Women in South and North Vietnam: A Population-Based Study. <i>Sexually Transmitted Diseases</i> , 2009, 36, 616-620.	1.7	4
292	Prevention of cervical cancer in women's hands: Mexico leads the way. <i>Lancet, The</i> , 2011, 378, 1829-1831.	13.7	4
293	How do international gastric cancer prevention guidelines influence clinical practice globally?. <i>European Journal of Cancer Prevention</i> , 2020, 29, 400-407.	1.3	4
294	Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2021, 224, 503-516.	4.0	4
295	Reproducibility of a Rapid Human Papillomavirus Test at Different Levels of the Healthcare System in Tanzania: The AISHA Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2261-2268.	2.5	3
296	Reduction of HPV16/18 prevalence in young women after eight years of three- and two-dose vaccination schemes. <i>Vaccine</i> , 2021, 39, 4419-4422.	3.8	3
297	Right-Sided Ectocervical Lesions May Be Associated with False-Negative Cytology Among Women with Histologic Cervical Intraepithelial Neoplasia 2 or 3. <i>Journal of Lower Genital Tract Disease</i> , 2003, 7, 175-183.	1.9	2
298	Lifestyle and dietary factors associated with serologically detected gastric atrophy in a Caucasian population in the GISTAR study. <i>European Journal of Cancer Prevention</i> , 2022, 31, 442-450.	1.3	2
299	Population-Based Strategies for Helicobacter pylori-Associated Disease Management: Latin American Perspective. , 2016, , 503-517.		1
300	Impact of operational factors on HPV positivity rates in an HPV-based screening study in Colombia. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 44-51.	2.3	1
301	Does Family History of Cancer Influence Undergoing Screening and Gastrointestinal Investigations?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 523-528.	0.9	1
302	HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial. <i>Npj Vaccines</i> , 2022, 7, 40.	6.0	1
303	Re: Muñoz et al., "Against which human papillomavirus types shall we vaccinate and screen? The international perspective." <i>Int J Cancer</i> 2004;111:278-85. <i>International Journal of Cancer</i> , 2005, 115, 670-670.	5.1	0
304	Intrauterine device and cervical cancer: we need more evidence " Authors' reply. <i>Lancet Oncology, The</i> , 2011, 12, 1186-1187.	10.7	0
305	Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention in Korea: A Randomized Controlled Clinical Trial. , 2017, , 315-330.		0
306	Title is missing!. , 2020, 15, e0237515.		0

#	ARTICLE	IF	CITATIONS
307	Title is missing!., 2020, 15, e0237515.		0
308	Title is missing!., 2020, 15, e0237515.		0
309	Title is missing!., 2020, 15, e0237515.		0
310	Factors Associated with False Negative Results in Serum Pepsinogen Testing for Precancerous Gastric Lesions in a European Population in the GISTAR Study. <i>Diagnostics</i> , 2022, 12, 1166.	2.6	0
311	Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial. <i>Sexually Transmitted Infections</i> , 0, , sextrans-2022-055434.	1.9	0